Human Pancreas 3D Tissue Imaging Using Visikol HISTO
Mike Johnson2020-01-24T10:46:11-05:00Whenever possible, we try to highlight the great work that our customers are doing in using our tissue clearing [...]
Visikol at Society of Toxicology Booth #663
Mike Johnson2020-01-14T08:23:54-05:00This year marks Visikol's fifth year attending SOT as an exhibitor and the focus for the company this year [...]
Visikol Expands Headquarters in Move to Hampton, NJ
Mike Johnson2020-01-10T12:34:40-05:00To kick off the new year, Visikol has announced that it has expanded its footprint in New Jersey by [...]
Come Visit Visikol at Booth #233 at SLAS in San Diego
Mike Johnson2019-12-18T08:52:29-05:00The Visikol team will be at the annual SLAS conference in San Diego where it will be presenting several [...]
Happy Holidays!
Mike Johnson2019-12-09T09:14:20-05:00We want to wish all of our friends, family, clients, customers and collaborators Happy Holidays! 2019 has been a [...]
Detecting Tumor Regions Using Convolutional Neural Networks
Mike Johnson2019-12-09T08:18:19-05:00Breast cancer is a serious disease with a wide array of treatment options depending on the severity of the [...]
In Vivo Relevancy of Three-Dimensional Cardiomyocyte Cell Culture Models
Mike Johnson2019-11-20T08:49:48-05:00In the drug discovery field, we typically work from high-throughput and low cost assays with poor in vivo relevancy [...]
Taking Advantage of Advances in Computer Hardware for Image Quantification
Mike Johnson2019-11-20T09:05:37-05:00Here at Visikol, image analysis is a central pillar of our experimental process, and how we turn complex in [...]
How to Design Your In Vitro Disease Model
Mike Johnson2019-11-20T08:12:34-05:00Choosing the appropriate amount of complexity to answer your biological question is critical when designing a disease model. The [...]
State of the 3D Cell Culture Field and Drug Discovery
Mike Johnson2019-11-13T15:01:30-05:00This week Visikol CEO Michael Johnson PhD was asked to speak as a keynote at the Millipore Sigma Scientific [...]